Antibody therapeutics targeting ion channels: are we there yet?

被引：29
|
作者：
Sun, Han
Li, Min [1 ]
机构：
[1] Johns Hopkins Univ, Dept Neurosci, High Throughput Biol Ctr, Baltimore, MD 21205 USA
来源：
ACTA PHARMACOLOGICA SINICA | 2013年 / 34卷 / 02期
基金：
美国国家卫生研究院;
关键词：
ion channel; antibody; autoimmune neurological disorder; channelopathy; protein-based therapeutics; ASPARTATE RECEPTOR MODULATOR; MONOCLONAL-ANTIBODY; CALCIUM-CHANNEL; SODIUM-CHANNELS; POLYCLONAL ANTIBODY; ENDOTHELIAL-CELLS; K+ CHANNELS; CA2+ ENTRY; P-TYPE; SUBUNIT;
D O I：
10.1038/aps.2012.202
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
The combination of technological advances, genomic sequences and market success is catalyzing rapid development of antibody-based therapeutics. Cell surface receptors and ion channel proteins are well known drug targets, but the latter has seen less success. The availability of crystal structures, better understanding of gating biophysics and validation of physiological roles now form an excellent foundation to pursue antibody-based therapeutics targeting ion channels to treat a variety of diseases.
引用
收藏
页码：199 / 204
页数：6
相关论文
共 50 条
  • [31] Targeting Ion Channels for Drug Discovery
    Clare, Jeffrey J.
    DISCOVERY MEDICINE, 2010, 9 (46) : 253 - 260
  • [32] Polarized targeting of ion channels in neurons
    Arnold, Don B.
    PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY, 2007, 453 (06): : 763 - 769
  • [33] Targeting exome sequences in congenital heart diseases: Are we there yet?
    Capitani, A.
    VIRCHOWS ARCHIV, 2016, 469 : S242 - S242
  • [34] Understanding and Targeting MET Signaling in Solid Tumors - Are We There Yet?
    Ariyawutyakorn, Witthawat
    Saichaemchan, Siriwimon
    Varella-Garcia, Marileila
    JOURNAL OF CANCER, 2016, 7 (06): : 633 - 649
  • [35] Erratum: Targeting the protein kinase C family: are we there yet?
    Helen J. Mackay
    Christopher J. Twelves
    Nature Reviews Cancer, 2008, 8 (3) : 1 - 1
  • [36] Ion channels as therapeutic antibody targets
    Hutchings, Catherine J.
    Colussi, Paul
    Clark, Theodore G.
    MABS, 2019, 11 (02) : 265 - 296
  • [37] Rational engineering of antibody therapeutics targeting multiple oncogene pathways
    Fitzgerald, Jonathan
    Lugovskoy, Alexey
    MABS, 2011, 3 (03) : 299 - 309
  • [38] Synthetic Biology, Directed Evolution, and the Rational Design of New Cardiovascular Therapeutics Are We There Yet?
    Mann, Douglas L.
    JACC-BASIC TO TRANSLATIONAL SCIENCE, 2023, 8 (07): : 905 - 906
  • [39] SMN-targeted therapeutics for spinal muscular atrophy: are we SMArt enough yet?
    Swoboda, Kathryn J.
    JOURNAL OF CLINICAL INVESTIGATION, 2014, 124 (02): : 487 - 490
  • [40] Strain imaging to detect cancer therapeutics-related cardiac dysfunction: are we there yet?
    Collier, Patrick
    Koneru, Srikanth
    Tamarappoo, Balaji
    Griffin, Brian
    FUTURE CARDIOLOGY, 2015, 11 (04) : 401 - 405
12345